Antiglucocorticoid treatment of depression: double-blind ketoconazole (Q41675968)

6 October 2017

title

Antiglucocorticoid treatment of depression: double-blind ketoconazole (English)

1 reference

6 October 2017

Wolkowitz OM

1 reference

6 October 2017

Reus VI

1 reference

6 October 2017

Chan T

1 reference

6 October 2017

Manfredi F

1 reference

6 October 2017

Raum W

1 reference

6 October 2017

Johnson R

1 reference

6 October 2017

Canick J

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

6 October 2017

published in

Biological Psychiatry

1 reference

6 October 2017

1 reference

6 October 2017

1 reference

6 October 2017

page(s)

1070-1074

1 reference

Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report.

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

7 January 2021

Steroids and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Treatment of major depression with metyrapone and hydrocortisone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Antiglucocorticoid treatments in psychiatry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

The DST as a predictor of outcome in depression: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

The use of ketoconazole as an inhibitor of steroid production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Ketoconazole administration in hypercortisolemic depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

Dehydroepiandrosterone (DHEA) treatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900267-4

10.1016/S0006-3223(98)00267-4

7 January 2021

Identifiers

DOI

1 reference

6 October 2017

1 reference